Forøgelse af resistens var mest almindelig i forsøgspersoner, hvis baseline- isolater havde adskillige protease- hæmmere - associerede mutationer, men < 40- gange formindsket følsomhed for lopinavir ved baseline.
Incremental resistance was most common in subjects whose baseline isolates had several protease inhibitor-associated mutations, but < 40-fold reduced susceptibility to lopinavir at baseline.